Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (3)

Search Parameters:
Keywords = total pancreatectomy with islet autologous transplantation

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
15 pages, 2206 KB  
Article
Inhibition of Toll-like Receptor 4 Using Small Molecule, TAK-242, Protects Islets from Innate Immune Responses
by Jordan Mattke, Carly M. Darden, Srividya Vasu, Michael C. Lawrence, Jeffrey Kirkland, Robert R. Kane and Bashoo Naziruddin
Cells 2024, 13(5), 416; https://doi.org/10.3390/cells13050416 - 27 Feb 2024
Cited by 4 | Viewed by 4010
Abstract
Islet transplantation is a therapeutic option to replace β-cell mass lost during type 1 or type 3c diabetes. Innate immune responses, particularly the instant blood-mediated inflammatory reaction and activation of monocytes, play a major role in the loss of transplanted islet tissue. In [...] Read more.
Islet transplantation is a therapeutic option to replace β-cell mass lost during type 1 or type 3c diabetes. Innate immune responses, particularly the instant blood-mediated inflammatory reaction and activation of monocytes, play a major role in the loss of transplanted islet tissue. In this study, we aimed to investigate the inhibition of toll-like receptor 4 (TLR4) on innate inflammatory responses. We first demonstrate a significant loss of graft function shortly after transplant through the assessment of miR-375 and miR-200c in plasma as biomarkers. Using in vitro models, we investigate how targeting TLR4 mitigates islet damage and immune cell activation during the peritransplant period. The results of this study support the application of TAK-242 as a therapeutic agent to reduce inflammatory and innate immune responses to islets immediately following transplantation into the hepatic portal vein. Therefore, TLR4 may serve as a target to improve islet transplant outcomes in the future. Full article
(This article belongs to the Special Issue Islet Transplantation)
Show Figures

Figure 1

20 pages, 345 KB  
Review
Total Pancreatectomy with Autologous Islet Cell Transplantation—The Current Indications
by Beata Jabłońska and Sławomir Mrowiec
J. Clin. Med. 2021, 10(12), 2723; https://doi.org/10.3390/jcm10122723 - 20 Jun 2021
Cited by 11 | Viewed by 5584
Abstract
Total pancreatectomy is a major complex surgical procedure involving removal of the whole pancreatic parenchyma and duodenum. It leads to lifelong pancreatic exocrine and endocrine insufficiency. The control of surgery-induced diabetes (type 3) requires insulin therapy. Total pancreatectomy with autologous islet transplantation (TPAIT) [...] Read more.
Total pancreatectomy is a major complex surgical procedure involving removal of the whole pancreatic parenchyma and duodenum. It leads to lifelong pancreatic exocrine and endocrine insufficiency. The control of surgery-induced diabetes (type 3) requires insulin therapy. Total pancreatectomy with autologous islet transplantation (TPAIT) is performed in order to prevent postoperative diabetes and its serious complications. It is very important whether it is safe and beneficial for patients in terms of postoperative morbidity and mortality, and long-term results including quality of life. Small duct painful chronic pancreatitis (CP) is a primary indication for TPAIT, but currently the indications for this procedure have been extended. They also include hereditary/genetic pancreatitis (HGP), as well as less frequent indications such as benign/borderline pancreatic tumors (intraductal papillary neoplasms, neuroendocrine neoplasms) and “high-risk pancreatic stump”. The use of TPAIT in malignant pancreatic and peripancreatic neoplasms has been reported in the worldwide literature but currently is not a standard but rather a controversial management in these patients. In this review, history, technique, indications, and contraindications, as well as short-term and long-term results of TPAIT, including pediatric patients, are described. Full article
(This article belongs to the Special Issue Islet Cell Transplantation for Treatment of Pancreatic Diseases)
8 pages, 212 KB  
Review
What Is New with Total Pancreatectomy and Autologous Islet Cell Transplantation? Review of Current Progress in the Field
by Xavier L. Baldwin, Brittney M. Williams, Beth Schrope and Chirag S. Desai
J. Clin. Med. 2021, 10(10), 2123; https://doi.org/10.3390/jcm10102123 - 14 May 2021
Cited by 8 | Viewed by 3231
Abstract
Patients with chronic pancreatitis have benefited from total pancreatectomy and autologous islet cell transplantation (TPAIT) since the 1970s. Over the past few decades, improvements have been made in surgical technique and perioperative management that have led to improved success of islet cell function, [...] Read more.
Patients with chronic pancreatitis have benefited from total pancreatectomy and autologous islet cell transplantation (TPAIT) since the 1970s. Over the past few decades, improvements have been made in surgical technique and perioperative management that have led to improved success of islet cell function, insulin independence and patient survival. This article focuses on recent updates and advances for the TPAIT procedure that continue to expand and innovate the impact on patients with debilitating disease. Full article
(This article belongs to the Special Issue Islet Cell Transplantation for Treatment of Pancreatic Diseases)
Back to TopTop